Applications of (R)-(-)-2-(2,5-Dihydrophenyl)Glycine in Industrial Manufacturing

(R)-(-)-2-(2,5-Dihydrophenyl)Glycine serves as a specialized chiral building block with established downstream utilization in several high-value chemical manufacturing sectors. This section details the practical industrial applications as validated by regulatory requirements, precision formulation needs, technical fit within modern production processes, and the diversity of certified end-use products.

1. Active Pharmaceutical Ingredient (API) Intermediate for CNS Drug Synthesis

Pharmaceutical manufacturers select (R)-(-)-2-(2,5-Dihydrophenyl)Glycine as a key asymmetric intermediate, particularly in the synthesis of third-generation glycine-site NMDA receptor antagonists and related research compounds targeting neurological conditions such as Alzheimer’s disease and neuropathic pain. Precision in chiral purity and low level of impurities allows integration directly into synthetic routes for target molecules where strict enantiomeric excess is required throughout multi-step organochemical synthesis.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP General Chapter <823> and relevant monographs
• European Pharmacopoeia (Ph. Eur.) General Requirements for API synthesis
• FDA 21 CFR Part 211 (cGMP for Finished Pharmaceuticals)

Typical usage ratio

• 0.3–1.2 molar equivalents per batch, calculated based on target CNS drug yield and adjusted for stepwise conversion efficiency in asymmetric hydrogenation or amide coupling reactions

Downstream process integration

• Introduced during the enantioselective key bond-forming stage; batch addition under anhydrous inert atmosphere; followed by chromatographic purification prior to final salt formation or direct coupling into the API scaffold

Final product types

• Chiral NMDA antagonist APIs
• Tetrazole derivatives for clinical trials
• Precursor libraries for neurotransmitter modulator research
• Small-molecule CNS therapeutic candidates

2. Fine Chemical Synthesis for Chiral Ligand Development

Custom synthesis labs and chemical R&D branches of fine chemical producers employ (R)-(-)-2-(2,5-Dihydrophenyl)Glycine to develop ligands, catalysts, and building blocks for stereoselective reactions. Its rigid aromatic core and S-stereochemistry allow for the construction of advanced intermediates where precise chiral orientation directly influences catalytic selectivity or further chemical elaboration in advanced material or pharmaceutical R&D.

Industry compliance standards

• ISO 9001:2015 Quality Management System (for chemical R&D and scale-up)
• REACH Registration, Evaluation, Authorisation and Restriction of Chemicals (EU markets)
• OECD Principles of Good Laboratory Practice (GLP) for development-stage chemistry
• Hazard Communication Standard (GHS/CLP labeling regulations)

Typical usage ratio

• 10–50 mmol per 100 mmol chiral ligand target batch, tuned for molar excess depending on ligand architecture and required purity of final product

Downstream process integration

• Introduced in asymmetric synthesis protocols involving Suzuki coupling, Buchwald–Hartwig amination, or peptide bond formation; primarily in gram-to-kilogram pilot campaigns

Final product types

• Chiral phosphine and amine ligands
• Stereodefined auxiliaries for organic synthesis
• Catalytically active peptide analogues
• Enantio-enriched scaffolds for further derivatization

3. Research-Grade Chemical for Academic and Industrial Life Science Studies

Universities and corporate research facilities require (R)-(-)-2-(2,5-Dihydrophenyl)Glycine for custom synthesis of neurotransmitter analogues, tool compounds for receptor binding studies, and for structure-activity relationship (SAR) investigations in life science research focused on glutamatergic signaling. The compound’s chiral purity and well-characterized impurity profile meet the accuracy expectations for biochemically relevant experiments and method development.

Industry compliance standards

• ISO/IEC 17025:2017 Accredited Testing and Calibration Laboratories
• National Institutes of Health (NIH) Guidelines for Chemical Use in Research
• European Chemicals Agency (ECHA) requirements for laboratory handling
• Material Safety Data Sheet (MSDS) compliance for academic procurement

Typical usage ratio

• 0.01–1.0 mmol per experiment, predetermined by experimental protocol for receptor binding or SAR studies; bulk orders vary based on research throughput

Downstream process integration

• Dissolved in DMSO/water for in vitro screening, incorporated in combinatorial synthesis for analog development, or added during solid-phase synthesis in small-scale automated reactors

Final product types

• Reference standards and calibration compounds
• Custom tool molecules for neurobiology assays
• Novel amino acid analogues for transporter studies
• Biochemical assay kits for university or biotech applications

4. Synthesis of Advanced Materials for Diagnostic Imaging Agents

Producers of diagnostic imaging precursors and functionalized small molecules incorporate (R)-(-)-2-(2,5-Dihydrophenyl)Glycine in the synthesis of radio-labeled compounds and fluorophore conjugates. Its defined stereochemistry is critical in certain advanced optical tracers and chelating agents, where chirality influences biological behavior, in vivo imaging contrast, or receptor specificity in preclinical diagnostic probe development.

Industry compliance standards

• ISO 13485:2016 Medical Devices Quality Management System (for diagnostic precursors)
• FDA 21 CFR Part 820 (Quality System Regulation)
• Ph. Eur. and USP requirements for Radiopharmaceuticals (for precursor compliance)
• Transport of Dangerous Goods (TDG) standard for radioactive material logistics

Typical usage ratio

• 0.1–0.7 molar equivalents per label synthesis batch; optimized based on radiolabeling or conjugation efficiency, with precise adjustments during method transfer from lab to plant

Downstream process integration

• Introduced in chelator or linker precursor formation, followed by conjugation to imaging moieties using activated esters or click chemistry; purification via preparative HPLC prior to radiolabeling or final formulation

Final product types

• Precursor molecules for PET and SPECT tracer synthesis
• Optical imaging agents with chiral specificity
• Derivatized amino acids for bioanalytical detection kits
• Functionalized probes used in target validation for medical imaging R&D